A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2011
10/06/2011	US20110243847 Imaging diagnostics by combining contrast agents
10/06/2011	US20110243846 Benzothiazole amides for detection of amyloid beta
10/06/2011	US20110243842 Mammalian receptor proteins; related reagents and methods
10/06/2011	US20110243840 Monoclonal antibodies against orthopoxviruses
10/06/2011	CA2795064A1 Pyripyropene derivative having acat2 inhibiting activity and stable to metabolizing enzymes
10/05/2011	EP2371861A1 Monoclonal antibodies against extracellular loops of C5aR
10/05/2011	EP2371839A1 Peptidomimetic protease inhibitors
10/05/2011	EP2371826A1 Novel fused ring compound and use thereof
10/05/2011	EP2371820A1 Optically active cyclic alcohol compound and method for preparing the same
10/05/2011	EP2371375A1 Peptide for inhibiting skin aging
10/05/2011	EP2371366A1 Heterocyclo inhibitors of potassium channel function
10/05/2011	EP2371365A1 Compositions comprising an epothilone and production methods
10/05/2011	EP2371361A1 Methods to mobilize progenitor/stem cells
10/05/2011	EP2370079A2 Hsp90 inhibitors for therapeutic treatment
10/05/2011	EP1787991B1 PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE
10/05/2011	EP1731042B1 Feed additive for laying hens and feed containing the additive
10/05/2011	EP1546136B1 Benzopyran derivatives substituted with secondary amines including imidazole, their preparation and pharmaceutical compositions containing them
10/05/2011	EP1411052B1 Benzo-fused 5-membered hetrocycle compounds,process for preparation of the same, and use thereof
10/05/2011	EP1406633B1 Enhanced drug delivery in transdermal systems
10/05/2011	EP1377276B1 Timed pulse release composition
10/05/2011	EP1295607B9 Antitumor effect potentiators
10/05/2011	EP1267945B1 Genetically modified cells expressing a tgf-beta inhibitor, the cells being lung cancer cells
10/05/2011	EP1246920B1 Prevention of affections associated with porcine circovirus-2
10/05/2011	CN1617704B Composition comprising at least one oxazolin for inhibiting langerhans cell migration, and uses thereof
10/05/2011	CN102209710A Pyrrolidines
10/05/2011	CN102209558A Pharmaceutical composition utilising combinations of variants of the gonadotropin-liberating hormone (gnrh) as immunogen
10/05/2011	CN102209547A Protein phosphatase inhibitor
10/05/2011	CN102206247A Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
10/05/2011	CN102205071A Chinese medicinal composition for treating thyroid cyst
10/05/2011	CN102205014A Method for processing rhizoma arisaematis
10/05/2011	CN101684083B Guanidinoalkanoylamino substituted tetracycline derivatives
10/05/2011	CN101524389B Use of Brassica rapa polysaccharide in preparation of anti-hypoxia drugs
10/05/2011	CN101442993B Adhesive preparation
10/05/2011	CN101380464B Method for treating a movement disorder
10/05/2011	CN101268848B Dew concentration beverage
10/05/2011	CN101224201B Application of dual inhibitor for dopamine and norepinephrine transfer protein
10/04/2011	US8030517 CCR9 inhibitors and methods of use thereof
10/04/2011	US8030484 Substituted triazines as prion protein ligands and their use to detect or remove prions
10/04/2011	US8030456 Nogo receptor antagonists
10/04/2011	US8030296 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase
10/04/2011	US8030275 Methods for treating obesity using fibroblast growth factor-like polypeptides
10/04/2011	US8030067 Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
10/04/2011	US8029823 Controlled release and taste masking oral pharmaceutical composition
10/04/2011	US8029768 pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.
10/04/2011	CA2669481C Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels
10/04/2011	CA2615917C Use of lipoxin compounds for inhibiting of tnf-(alpha)initiated neutrophil response
10/04/2011	CA2494536C A 12-membered ring macrolide active substance
10/04/2011	CA2491079C Therapeutic piperazine derivatives useful for treating pain
10/04/2011	CA2478099C Inhibitors
10/04/2011	CA2453837C Treatment for attention-deficit hyperactivity disorder using eltoprazine and related compounds
10/04/2011	CA2438520C Phthalazinone-piperidino-derivatives as pde4 inhibitors
10/04/2011	CA2434773C Piperazinylcarbonylquinolines and -isoquinolines
10/04/2011	CA2426031C 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
09/2011
09/29/2011	WO2011119929A2 Composition for enhancing athletic performance
09/29/2011	WO2011118843A1 Glutamate derivatives or salts thereof
09/29/2011	WO2011118779A1 Pharmaceutical composition for treatment and prevention of herpesvirus infections
09/29/2011	WO2011118759A1 Benzanilide derivative
09/29/2011	WO2011118682A1 Aptamer for ngf and use thereof
09/29/2011	WO2011118672A1 Plasma kallikrein inhibitor
09/29/2011	WO2011117305A1 Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates
09/29/2011	WO2011073981A3 Betahistine in compositions and methods for treating somnolence
09/29/2011	WO2011059821A3 Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis
09/29/2011	US20110239318 Methods for producing fish with high lipid content
09/29/2011	US20110237792 Quinoline derivatives and their use as 5-ht6 ligands
09/29/2011	US20110237672 Use of a cysteine-containing substance to increase the ventilatory activity and erythropoietin production
09/29/2011	US20110237661 Supplement Composition and Method of Use
09/29/2011	US20110237651 Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
09/29/2011	US20110237650 Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
09/29/2011	US20110237648 Rna interference in skin indications
09/29/2011	US20110237645 USE OF RNAi TECHNOLOGY TO INHIBIT ASIC3
09/29/2011	US20110237628 Cyclopentyl- and cycloheptylpyrazoles
09/29/2011	US20110237617 Thieno[2,3-c] isoquinolines for use as inhibitors of parp
09/29/2011	US20110237578 Amide compounds, compositions and uses thereof
09/29/2011	US20110237574 Use of modified pyrimidine compounds to promote stem cell migration and proliferation
09/29/2011	US20110237571 Phthalazine derivatives
09/29/2011	US20110237563 Fast dissolving drug delivery systems
09/29/2011	US20110237522 Neutral nanotransporters
09/29/2011	US20110237498 Soluble polypeptides for use in treating autoimmune and inflammatory disorders
09/29/2011	US20110237447 Method of determining chromatin structure
09/29/2011	US20110236511 Herbal formulations
09/29/2011	US20110236502 Vitamin Strip (V1)
09/29/2011	US20110236483 Rna vector therapy
09/29/2011	US20110236432 Coated Medical Device and Method of Coating a Medical Device to Reduce Fibrosis and Capsule Formation
09/29/2011	US20110236383 Protein Formulation
09/29/2011	US20110236352 PEGylation by the Dock and Lock (DNL) Technique
09/29/2011	US20110236346 Compositions and Methods for Treatment of Radiation Exposure
09/29/2011	US20110236320 Ultrasound Contrast Agents And Process For The Preparation Thereof
09/29/2011	US20110236316 Peptide targeting imaging agents and methods of use thereof
09/29/2011	US20110236308 Aryl Bidentate Isonitriles and Their Uses
09/29/2011	CA2831265A1 Composition for enhancing athletic performance
09/29/2011	CA2794199A1 Aptamer for ngf and use thereof
09/28/2011	EP2368910A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
09/28/2011	EP2368906A1 Fas associated factor 1
09/28/2011	EP2368902A2 Insulin and IGF-1 receptor agonists and antagonists
09/28/2011	EP2368901A1 Peptidomimetic protease inhibitors
09/28/2011	EP2368898A1 Compositions and methods for counteracting effects of reactive oxygen species and free radicals
09/28/2011	EP2368889A1 Inhibitors of tyrosine kinases
09/28/2011	EP2368880A1 6-(Heterocycle-Substituted Benzyl)-4-Oxoquinoline Compound and Use of the Same as HIV Integrase Inhibitor
09/28/2011	EP2368878A1 Peptidomimetic protease inhibitors
09/28/2011	EP2368877A1 Chiral intermediates for the preparation of peptidomimetic protease inhibitors

1 ... 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 ... 1564